1. Preoperative pulmonary function tests predict mortality after surgical or transcatheter aortic valve replacement 
Matthew C. Henn, MD, Alan Zajarias, MD, Brian R. Lindman, MD, Jason W. Greenberg, BS, Spencer J. Melby, MD, Nishath Quader, MD, Anna M. Vatterott, MPH, Cassandra Lawler, MSN, Marci S. Damiano, RN, MSN, Eric Novak, MS, John M. Lasala, MD, Marc R. Moon, MD, Jennifer S. Lawton, MD, Ralph J. Damiano, MD, Hersh S. Maniar, MD 
The Journal of Thoracic and Cardiovascular Surgery 
Volume 151, Issue 2, Pages e2 (February 2016)
DOI: /j.jtcvs
Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

2. Figure 1
CLD and mortality after AVR. Time-to-event curves are shown based on Kaplan-Meier estimates with patients stratified by STS lung disease severity for (A) TAVR and SAVR combined, (B) TAVR alone, and (C) SAVR alone. AVR, Aortic valve replacement.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

3. Figure E1
PFT metrics and mortality after AVR. Time-to-event curves are shown based on Kaplan-Meier estimates when patients who underwent TAVR or SAVR are stratified into quartiles based on (A) percent predicted forced expiratory volume in 1 second (FEV1), (B) diffusion capacity of the lung for carbon monoxide (DLCO), and (C) forced vital capacity (FVC).
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions

4. Chronic lung disease severity and all-cause mortality after aortic valve replacement.
The Journal of Thoracic and Cardiovascular Surgery  , e2DOI: ( /j.jtcvs )
Copyright © 2016 The American Association for Thoracic Surgery Terms and Conditions